SeekingAlpha · Aug 13, 2026
NASDAQ · CPIX
Cumberland Pharmaceuticals Inc.
Healthcare · Drug Manufacturers - Specialty & Generic
$6.39
Down-$0.09 (-1.39%)
Updated Sep 13, 2026, 11:45 PM
SID Score
5.5/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 37.02M
- P/E ratio
- -11.12
- Dividend yield
- 46.95%
- 52-week range
- $1.85 – $9.28
- Volume
- 16.65K
- Avg. volume
- 54.96K
Price performance
CPIX price history
1M range · 19 trading sessions · Daily adjusted prices
CPIX closed at $6.39 after 19 trading sessions, down 16.80% for the selected period.
- Last close
- $6.39
- Period change
- -16.80%
- Period low
- $6.29
- Period high
- $8.97
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 11, 2026 | $6.61 | $6.75 | $6.38 | $6.39 | 16.65K |
| Sep 10, 2026 | $6.25 | $6.505 | $6.24 | $6.48 | 41.27K |
| Sep 9, 2026 | $6.59 | $6.72 | $6.28 | $6.29 | 19.74K |
| Sep 8, 2026 | $6.66 | $6.8844 | $6.47 | $6.62 | 28.15K |
| Sep 4, 2026 | $6.75 | $6.90 | $6.65 | $6.79 | 14.08K |
| Sep 3, 2026 | $6.52 | $6.775 | $6.41 | $6.75 | 17.74K |
| Sep 2, 2026 | $6.67 | $6.76 | $6.28 | $6.52 | 56.62K |
| Sep 1, 2026 | $6.70 | $6.905 | $6.42 | $6.56 | 77.78K |
| Aug 31, 2026 | $8.21 | $8.50 | $6.58 | $6.69 | 190.73K |
| Aug 28, 2026 | $8.70 | $9.16 | $8.44 | $8.46 | 47.94K |
| Aug 27, 2026 | $8.94 | $9.1872 | $8.36 | $8.65 | 91.02K |
| Aug 26, 2026 | $8.72 | $9.2799 | $8.57 | $8.97 | 110.48K |
| Aug 25, 2026 | $7.89 | $8.70 | $7.63 | $8.70 | 112.32K |
| Aug 24, 2026 | $7.67 | $8.00 | $7.51 | $7.84 | 25.77K |
| Aug 21, 2026 | $7.52 | $7.65 | $7.34 | $7.65 | 34.8K |
| Aug 20, 2026 | $7.59 | $7.92 | $7.46 | $7.50 | 130.22K |
| Aug 19, 2026 | $7.67 | $7.87 | $7.57 | $7.65 | 69.47K |
| Aug 18, 2026 | $7.59 | $8.00 | $7.59 | $7.63 | 41.02K |
| Aug 17, 2026 | $7.68 | $8.055 | $7.58 | $7.68 | 160.24K |
Latest CPIX news
The latest Smart Investors Daily articles mentioning CPIX.
Stock researchCompany · Overview
CPIX research
Overview
Company profile and research snapshot.
Company profile
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment which is specialty pharmaceutical products. The company's target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The company promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. The company's revenue is derived from the product sales of FDA-approved pharmaceutical brands. Its brands include Acetadote, Caldolor, Kristalose, Omeclamox, Sancuso, Vaprisol and Vibativ.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Dec 3, 2019 | B. Riley | Buy | — |
| Nov 18, 2019 | B. Riley FBR | Buy | — |
| Aug 17, 2018 | B. Riley FBR | Buy | — |
| Apr 17, 2018 | B. Riley FBR | Buy | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Aug 4, 2026
Cumberland Pharmaceuticals Inc. (CPIX) Q2 2026 Earnings Call Transcript
Cumberland Pharmaceuticals Inc. (CPIX) Q2 2026 Earnings Call August 4, 2026 4:30 PM EDTCompany ParticipantsA.
Benzinga · Aug 4, 2026
Cumberland Q2 Adj. EPS $(0.20) Down From $(0.13) YoY, Sales $166.458K Down From $380.797K YoY
Cumberland (NASDAQ:CPIX) reported quarterly losses of $(0.20) per share. This is a 53.85 percent decrease over losses of $(0.13) per share from the same period last year. The company reported $166.458 thousand in sales
Benzinga · Jul 13, 2026
Cumberland Pharmaceuticals Declares $1.50/Share Special Dividend
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), an innovation-focused biopharmaceutical company developing new products for rare diseases, announced today that its Board of Directors has authorized and declared a special
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
